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Background: An andrographolide analogue, 3, 19-isopropylideneandrographolide (IPAD), exerts an inhibitory effect
on replication of wild-type herpes simplex virus serotype 1 (HSV-1). In this study, we examined the anti-viral activity
of IPAD on HSV wild types (HSV-1 strain KOS and HSV-2 clinical isolate) and HSV-1 drug-resistant strains (DRs). Synergistic
effects of IPAD with acyclovir (ACV) were also evaluated.
Methods: MTT and cytopathic effect (CPE) reduction assays were performed to determine cytotoxicity and
anti-viral activities, respectively. A combination assay was used to determine synergistic effects of IPAD and
ACV. Presence of viral DNA and protein in experimental cells was investigated using the polymerase chain
reaction and western blotting, respectively.
Results: A non-cytotoxic concentration of IPAD (20.50 μM) completely inhibited CPE formation induced by
HSV wild types and HSV-1 DRs after viral entry into the cells. The anti-HSV activities included inhibition of
viral DNA and protein synthesis. The minimum inhibitory concentrations of ACV for HSV wild types and
HSV-1 DRs were 20.20 and 2,220.00 μM, respectively. Combination of ACV with IPAD showed synergistic
effects in inhibition of CPE formation, viral DNA and protein synthesis by HSV wild types as well as HSV-1
DRs. For the synergistic effects on HSV wild types and HSV-1 DRs, the effective concentrations of ACV were
reduced.
Conclusions: These results showed the inhibitory potential of IPAD on HSV wild types and HSV-1 DRs and
suggested that IPAD could be used in combination with ACV for treatment of HSV-1 DRs infections.Background
Herpes simplex viruses (HSV) are common human path-
ogens that cause herpes labialis, herpes genitalis, kera-
titis and encephalitis. According to epidemiological
surveys, the HSV infection rate has continuously in-
creased in most countries [1]. Nucleoside analogs,
acyclovir (ACV) and others such as penciclovir, valaci-
clovir, and famciclovir, have been approved for treatment
of HSV infections worldwide, but severe side effects may
occur [2-4]. Moreover, long-term prophylactic and* Correspondence: chapie@kku.ac.th
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unless otherwise stated.curative ACV treatments may result in the emergence of
HSV drug resistance (DRs), especially among immuno-
compromised individuals such as HIV-infected patients
and transplant recipients. Resistance of HSV to ACV has
been reported in 5-30% of cases, mainly among im-
munocompromised patients and particularly in allogen-
eic bone marrow transplant patients [5]. ACV is an
analogue of guanosine that requires activation through
triphosphorylation. The first phosphorylation is mainly
achieved by HSV thymidine kinase (TK), encoded by the
UL23 gene, whereas subsequent phosphorylations are
carried out by host cellular kinases [6]. The ACV active
form is then incorporated by the viral DNA polymerase,
encoded by the UL30 gene, and finally disrupts viral
genome replication by a chain-termination mechanism.
In accordance with this mechanism of action, viralntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mapped both in UL23 and UL30 genes, but 95% of HSV
strains exhibiting resistance to ACV harbor mutations
within the UL23 gene alone. These mutations lead to the
production of TK with deficient or altered phosphoryl-
ation activity.
There is an urgent need for cheap, less toxic alternative
agents to control and prevent HSV infection and its trans-
mission. Andrographolide (Androg) is a bioactive ent-lab-
dane diterpene isolated from Andrographis paniculata
Nees, Acanthaceae and has been used to treat various dis-
eases traditionally in the Southeast Asian countries, India
and China. The pure form of Androg and its derivatives
were isolated and already characterized [7]. In our recent
studies, 3, 19-isopropylideneandrographolide (IPAD), an
analogue of Androg, was found to exert an absolute in-
hibitory effect on HSV-1 post-infection at the concentra-
tion of 11.96 μM [7,8]. IPAD affects the early steps of
DNA replication in HSV-1. Its action influences viral
DNA synthesis and expression of gC and gD [7].
ACV and IPAD have different structures. This likely
means that their modes of action also differ. In this
study, IPAD and IPAD in combination with ACV were
tested for anti-viral activity against HSV wild types




An African green monkey kidney cell line (Vero) was
maintained in Dulbecco’s Modified Eagle Medium
(DMEM; Gibco-BRL, Gaithersburg, MD, USA) supple-
mented with 10% fetal bovine serum (FBS; Gibco-BRL,
Gaithersburg, MD, USA), 100 units/ml penicillin G,
100 μg/ml streptomycin, 40 μg/ml gentamicin and
0.25 μg/ml amphotericin B.
Viruses
HSV wild types used in this study were HSV-1 strain
KOS and HSV-2 clinical isolate (kindly provided by Prof.
Pilaipan Puthavathana, Mahidol University, Thailand).
HSV-1 DRs, kindly provided by Prof. Donald Coen (Bio-
logical Chemistry & Molecular Pharmacology, Harvard
Medical School, Boston, USA.), were ACGr4 (acyclovir-
resistant with thymidine kinase (TK)-deficient), dlsptk
(acyclovir-resistant with TK-deletion) and dxpIII (phos-
phonoacetic acid and phosphonoformate-resistant). The
viruses were propagated on Vero cells and viral titers
were determined by plaque assays on Vero cells. Ali-
quots of viral stock were stored at -80°C until use.
Compound
IPAD was isolated and its structure was identified by a
team at the Faculty of Pharmaceutical Sciences, KhonKaen University, using the procedures described previ-
ously [7,8]. The final concentration of DMSO was less
than 0.1% and had no toxic effects on the cells.
Cytotoxicity assay
The effect of IPAD and ACV on cell viability was deter-
mined by MTT assay using 3-(4,5-dimethylthiazole-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) (SIGMA®
(Sigma-Aldrich, Saint Louis, Missouri, USA). Vero cells
were seeded in 96-well tissue-culture plates (104 cells/
well) and grown at 37°C for 1 day. The culture media
were replaced with fresh media containing various con-
centrations of IPAD (7.80 to 820.00 μM) and ACV (50
to 6,400 μM). After 72 h incubation, the media were re-
placed with 15 μl of 5 mg/ml MTT in each well and the
cells were incubated at 37°C for 4 h. DMSO was added
and incubated at room temperature for 15 min. The op-
tical density (OD540 nm) was measured by a microplate
reader (Tecan-Sunrise-Microplate Reader). Cell viability
of the treated cells was calculated by percentage of mean
value of the OD540 nm compared with the cell control,
which was set at 100%. Dose-response curves of three
independent experiments were plotted to calculate the
50% cytotoxic concentration (CC50) of IPAD and ACV.
Anti-HSV activity at the pre-entry step
Vero cells were seeded in 96-well tissue-culture plates
(104 cells/well) and grown at 37°C for 1 day. HSV was
incubated with IPAD at 37°C for 1 h. Then the mixture
was added to Vero cells at 0.01 MOI of HSV and incu-
bated at 37°C for 1 h. After removing the mixture, the
cells were washed three times with PBS and incubated in
media containing 0.8% carboxymethyl cellulose (CMC).
Dextran sulfate (10 μM) was used as a positive control.
Cytopathic effect (CPE) was observed under an inverted
microscope at 48 and 72 h post-infection (h.p.i.). The
foci of CPE were counted under an inverted microscope
and compared with the virus control at 72 h.p.i.
Anti-HSV activity at the post-entry step
Vero cells were seeded in 96-well tissue-culture plates
(104 cells/well) and grown at 37°C for 1 day. HSV at 0.01
MOI were adsorbed on Vero cells at 37°C for 1 h. After
the unadsorbed viruses had been removed, the infected
cells were incubated in media containing 0.8% CMC and
IPAD at 37°C for 72 h. ACV (20.20 μM) was used as the
positive control. The foci of CPE were counted under an
inverted microscope and compared with the virus con-
trol at 72 h.p.i. The cells were harvested for DNA and
protein extraction.
HSV detection by polymerase chain reaction (PCR)
Total DNA was extracted from the tested cells using the
PUREGENE DNA purification system (PUREGENE®; Gentra
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gene, UL30 was amplified using a forward primer
(GTGTTGTGCCGCGGTCTCAC) and a reverse primer
(GGTGAACGTCTTTTCGAACTC) with an expected
product size about 123 bp. A housekeeping gene, β-actin
was used as the internal control and was amplified using a
forward primer (TCACCCACACTGTGCCCATCTACG)
and a reverse primer (CAGCGGAACCGCTCATTGC-
CAATG) with an expected product size about 294 bp. The
amplified PCR product was visualized by electrophoresis in
a 1.5% agarose gel.
HSV detection by western blotting
The tested cells were lysed with lysis buffer and proteins
were extracted. The presence of HSV-1 glycoprotein D
(gD) in the extracted protein was determined by western
blotting using a primary polyclonal antibody against gD
(kindly provided by Prof. Gary H. Cohen and Prof. Roselyn
J. Eisenberg, University of Pennsylvania, Philadelphia,
Pennsylvania, USA and the secondary antibody, horserad-
ish peroxidase (HRP)-conjugated goat anti-rabbit im-
munoglobulin G (Zymed®; Invitrogen Co., California,
USA) according to the protocol of the previous study [8].
Evaluation of drug synergy
Potential synergistic effects of ACV and IPAD on HSV
infections were evaluated at the post-entry step using
the CPE reduction assay. Each drug alone, or their com-
bination, was tested at the equipotency ratio based on its
corresponding IC100, IC50 and IC10 values. The synergis-
tic effect of ACV and IPAD was calculated by using a
combination index (CI) as described previously [9]. A CI
value of 1 indicates an additive effect; CI < 1 indicates a
synergistic effect, and CI > 1 indicates an antagonistic ef-
fect. Viral DNA and protein were determined using PCR
and western blotting to confirm the inhibitory effect.
Results
Cytotoxicity and anti-HSV activity of IPAD
The maximum concentration of IPAD which did not
affect Vero cell viability was 22.55 μM while the highest





HSV-2 HSV-1 KOS H
IC50 (μM) SI
c IC50 (μM) SI
c I
IPAD 39.71 18.01 2.20 16.96 2.34 1
ACV >6,400 0.80 >8,000 0.49 >13,061 5
The value represents mean of three independent experiments.
aCytotoxic effect was determined using the MTT assay. CC50 was the concentration
bAnti-viral activity was determined using the CPE reduction assay. IC50 was the con
to controls.
cSI (selective index) was calculated as the ratio of CC50 to IC50.affect Vero cell viability. The CC50 of IPAD and ACV
were 39.71 μM and >6,400 μM, respectively (Table 1).
To determine the anti-viral activity of IPAD against
HSV wild types and HSV-1 DRs at the pre- and post-
entry steps, a CPE reduction assay was performed. At
the pre-entry step, 10 μM dextran sulfate (positive con-
trol) exhibited 100% inhibition whereas 20.50-22.55 μM
IPAD exerted about 50-60% inhibition against both HSV
wild types and HSV-1 DRs. In contrast, ACV had little
anti-HSV activity at the pre-entry step (Figure 1A). In
the present study, we also performed virus binding and
internalization assays separately and the results showed
that there were no significant effects in these steps of
the virus multiplication cycle (data not shown). At the
post-entry step (Figure 1B), the lowest concentrations of
IPAD and ACV which completely inhibited CPF forma-
tion by HSV wild types were 20.50 μM and 22.20 μM,
respectively. IPAD at 20.50 μM also exerted 100% inhib-
ition against HSV-1 DRs while for ACV, a concentration
of at least 2,220.00 μM was required to exert complete
inhibition against HSV-1 DRs.
IC50 values of IPAD, which were determined at the
post-entry step using the CPE reduction assay, were 17-
18 μM according to the target virus strains as shown in
Table 1. Interestingly, the IC50 as well as SI values of
IPAD against HSV wild types and HSV-1 DRs were not
different (Table 1). In contrast, the IC50 and SI values of
ACV against HSV wild types and HSV-1 DRs were
markedly different. The IC50 values for ACV against
HSV wild types were less than 1.0 μM, whereas those
against HSV-1 DRs were more than 160 μM (Table 1).
To confirm the inhibitory effect of IPAD against both
HSV wild types and HSV-1 DRs at the post-entry step,
the presence of HSV DNA and protein in infected cells
was examined using PCR and western blotting. Even
though IPAD exhibited 100% inhibition of CPE forma-
tion, a small amount of viral DNA was detected at 72 h.
p.i. (Figure 2). In contrast, ACV showed complete inhib-
ition of viral DNA synthesis. However, IPAD and ACV
significantly suppressed the expression of viral protein
as shown in Figure 3. This result suggests that the in-
hibitory effect of IPAD may be exerted at an early stepof IPAD and ACV at the post-entry step
SV-1 ACGr4 HSV-1 dlsptk HSV-1 dxpIII
C50 (μM) SI
c IC50 (μM) SI
c IC50 (μM) SI
c
7.89 2.22 16.86 2.36 17.12 2.32
75.91 >11.11 450.25 >14.21 161.45 >39.64
reducing cell viability by 50% relative to controls.
centration that reduced HSV-induced CPE formation by 50% relative
Figure 1 Effects of IPAD and ACV on HSV wild types and HSV-1 DRs determined using the CPE reduction assay. A: pre-entry step.
B: post-entry step.
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that of ACV.
Synergistic effects of acyclovir and IPAD on HSV
infections
The combined effect of ACV and IPAD on HSV infec-
tions was examined at the post-entry step using the CPE
reduction assay and confirmed by PCR and western blot-
ting. Table 2 shows synergistic effects and CI values ofFigure 2 Effects of IPAD and ACV on HSV DNA synthesis in the post-i
including HSV-1 KOS and HSV-2 clinical isolate. B: HSV-1 DRs including HSV-1
= virus control, N = negative control.ACV and IPAD combined at different concentrations
and determined using the CPE reduction assay. When
IC10 concentrations of ACV and IPAD were used in the
combination assay, they still exerted complete inhibition
against HSV wild types and HSV-1 dxpIII infections. CI
values < 1 indicate synergism between these two com-
pounds. When used in combination with IPAD, the con-
centration of ACV required for complete inhibition of
HSV-1 dxpIII was reduced from 2,220.00 to 18.70 μM.nfection treatment with IPAD and ACV for 72 h. A: HSV wild types
ACGr4, HSV-1 dlsptk and HSV-1 dxpIII. M =marker, P = positive control, VC
Figure 3 Effects of IPAD and ACV on HSV protein expression in the post-infection treatment with IPAD and ACV for 72 h. Treated and
untreated cells were analyzed by SDS–PAGE/western blotting using specific antibodies for viral (gD) and cellular (β-actin) proteins. Lane 1: viral
control; Lane 2: HSV-infected cells treated with IPAD (20.50 μM); Lane 3: HSV-infected cells treated with ACV (20.20 μM); Lane 4: cellular control.
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ACV and IPAD were reduced more than 10 times when
compared with a single drug assay (Table 2). This result
indicated the increased SI of IPAD from 2 (the single
drug assay) to more than 20 (the combination assay).
The synergistic effects of ACV and IPAD against HSV
wild types and HSV-1 DRs were confirmed by testing
for the presence of viral DNA and protein in experimen-
tal cells. Viral DNA synthesis was completely inhibited
when IPAD and ACV were combined, each at their IC50
concentration (Figure 4). These concentrations also
completely inhibited production of the viral protein ac-
cording to western blotting (Figure 5).
Discussion
This study demonstrated the inhibitory effects of IPAD,
a semi-synthetic compound derived from Androg, on
HSV wild types and HSV-1 DRs. The effects included in-
hibition of CPE formation, viral protein, gD synthesis
and viral DNA synthesis. IPAD was spectacularly effect-
ive in inhibiting HSV-1 DRs, presumably involving a
mode of action different from ACV or phosphonoacetate.
The combination of ACV with IPAD produced synergistic
effects, reducing concentrations of both compounds re-
quired for complete inhibition of DNA replication and late
protein synthesis of HSV-1 wild types and HSV-1 DRs at
the post-entry step of infection.
The anti-viral effects of IPAD against HSV-1 KOS
(wild type) at the virus replication and releasing stages
was previously reported [8]. In the present study, anti-
viral activity of IPAD against HSV wild types and HSV-1
DRs was evaluated. IPAD showed higher cytotoxicity to-
wards Vero cells than did ACV. However, IPAD at
20.50 μM, which was not cytotoxic to Vero cells, dis-
played anti‐viral effect at the post-entry step againstHSV wild types and HSV-1 DRs (Figure 1B) correspond-
ing with the previous report [8]. This was confirmed by
demonstration of significant reduction of HSV DNA and
protein synthesis in all HSV strains (Figures 2 and 3).
Interestingly, IPAD exhibited highly anti-herpetic activity
against HSV-1 DRs, not only the acyclovir-resistant
strains (HSV-1 ACGr4 and HSV-1 dlsptk), but also the
phosphonoacetic acid-resistant strain (HSV-1 dxpIII).
This result suggests that the inhibitory targets of IPAD
are probably different from those of acyclovir and phos-
phonoacetic acid. Recently, some compounds that
showed an inhibitory effect on HSV drug-resistant
strains were reported. Glucoevatromonoside, a cardeno-
lide isolated from a Brazilian cultivar of Digitalis lanata,
was reported to inhibit HSV-1 KOS, HSV-1 29R (acyclo-
vir-resistant) and HSV-2 333 by the inhibition of viral
proteins synthesis [10]. Oxyresveratrol, derived from a
Thai medicinal plant, inhibited HSV replication and viral
late protein synthesis with pretreatment in a one-step
growth assay of HSV-1 and HSV-2 [11]. The inhibitory
effects of plant-derived polyphenolic compounds, castala-
gin, vescalagin and grandinin (C-glucosidic ellagitannins
containing nonahydroxyterphenoyl), on the replication of
ACV-resistant strains of HSV-1and HSV-2 were shown in
MDBK cells [12]. The anti-viral activity of Androg or its
derivatives against other viruses has also been reported.
Androg effectively inhibited the expression of Epstein–
Barr virus (EBV) lytic proteins, Rta, Zta and EA-D, during
the viral lytic cycle in P3HR1 cells. Transient transfection
analysis revealed that the lack of expression of Rta, Zta
and EA-D is caused by the inhibition of the transcription
of BRLF1 and BZLF1, two EBV immediate early genes that
encode Rta and Zta, respectively [13]. The 14-α-lipoyl
andrographolide (AL-1) could directly interfere with an in-
fluenza hemagglutinin to block binding to cellular















IC100xIC100 20.50 20.20 100
IC50xIC50 18.01 0.80 100






IC100xIC100 20.50 20.20 100
IC50xIC50 16.96 0.49 100






IC100xIC100 20.50 2,220.00 100
IC50xIC50 17.89 575.91 100






IC100xIC100 20.50 2,220.00 100
IC50xIC50 16.86 450.25 98.55






IC100xIC100 20.50 2,220.00 100
IC50xIC50 17.12 161.45 100
IC10xIC10 14.90 18.70 100 < 1 synergism
17.12 0.16 50
0.009 161.45 50
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Figure 4 Combined effects of IPAD and acyclovir on HSV DNA synthesis. Vero cells infected with HSV wild types and HSV-1 DRs were treated
with IPAD and ACV in various concentrations for 72 h and analyzed by PCR using specific primers for viral (HSV DNA polymerase) and cellular (β-actin)
genes. A: HSV wild types. B: HSV-1 DRs.
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action [14].
Some studies have reported that the combination of
oxyresveratrol and ACV exhibited a synergistic effect
against HSV-1 [11] and that the combination of ellagi-
tannin(s) and ACV exhibited a much stronger synergis-
tic effect against ACV-resistant HSV-1 compared to
ACV-resistant HSV-2 [12]. In the present study, the po-
tential synergistic effects between IPAD and acyclovir
were also observed against both HSV wild types and
HSV-1 DRs (Table 2). In addition, this synergistic effectFigure 5 Combined effects of IPAD and acyclovir on HSV protein syn
treated with IPAD combined with ACV in various concentrations for 72 h a
for viral (gD) and cellular (β-actin) proteins. Lane 1: untreated HSV-infected
and IPAD (IC100); Lane 3: HSV-infected cells treated with ACV (IC50) and IPAD (not only reduced the effective concentration of ACV but
also of IPAD and increased the SI value for IPAD from 2
to 20.
ACV is a nucleoside analog that exhibits anti-herpetic ac-
tivity after phosphorylation by viral TK. The acyclovir tri-
phosphate then interferes with viral DNA polymerization
through competitive inhibition with guanosine triphosphate
and obligatory DNA chain termination [3]. Base on the in-
hibitory effect of IPAD on viral DNA and protein synthesis
of HSV-1 DRs (Figures 4 and 5), this study suggested that
IPAD and ACV have different targets. Therefore, thethesis. Vero cells infected with HSV wild types and HSV-1 DRs were
nd analyzed by SDS–PAGE/western blotting using specific antibodies
Vero cell control; Lane 2: HSV-infected cells treated with ACV (IC100)
IC50); Lane 4: HSV-infected cells treated with ACV (IC10) and IPAD (IC10).
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development of drug (ACV) resistance. Lower doses of
ACV and IPAD, possible when these are used in combin-
ation, can also reduce any cytotoxic effects of the drugs.
Conclusions
In summary, the anti-viral activity of IPAD likely in-
volves a mode of action different from ACV or phospho-
noacetate. The combination of IPAD with ACV could
reduce the concentration of ACV required for treatment
and suggests that IPAD can be used in combination with
ACV for inhibition of herpes infections, especially HSV-
1 DRs.
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